Universitaetsklinikum Heidelberg AöR — Sponsor Intelligence | 38 EU Trials

Filter these 38 trials by condition, phase, country and more.

Open in Search →

38 Registered trials

22 Recruiting

13 Completed trials

8 Countries active

77 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase IV

Phase I (Other)

Phase III: 10 Phase II/III: 1 Phase II: 12 Phase I/II: 5 Phase IV: 4 Phase I: 1 Phase I (Other): 4 Other: 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

13 of 13 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Idiopathic inflammatory myopathy 2 Systemic lupus erythematosus 2 Psoriatic arthropathy 1 Arteriosclerosis coronary artery 1 Colorectal cancer metastatic 1 Colitis ulcerative 1 Chronic kidney disease 1 Hypoplastic left heart syndrome 1 Rheumatoid arthritis 1 Axial spondyloarthritis 1 Glioblastoma 1

Top IMPs

BORTEZOMIB 4 LENALIDOMIDE 4 ISATUXIMAB 3 DARATUMUMAB 2 GUSELKUMAB 2 IXEKIZUMAB 2 TECLISTAMAB 2 UPADACITINIB 2 ABATACEPT 1 ANAKINRA 1 APREMILAST 1 ASCORBIC ACID 1

All trials

38 total

A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke… Pending

2024-514682-19-00 Phase III 2 countries
Multi-center, single-arm, phase II clinical trial evaluating efficacy and in-vivo homing of adoptively transferred autologous ex-vivo expand… Pending

2025-520628-11-00 Phase II 1 country AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+
Efficacy and safety of SP16 in preventing Acute Kidney Injury in at-risk subjects with chronic kidney disease undergoing elective cardiac su… Pending

2025-522491-89-00 Phase II 1 country SP16-3M
Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending

2025-523990-40-00 Phase III 1 country BORTEZOMIB; DARATUMUMAB; LENALIDOMIDE; TECLISTAMAB
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) Recruiting

2024-516896-34-00 Phase I/II 5 countries TOVORAFENIB; ULIXERTINIB; VINBLASTINE SULFATE
A multiCenter phase I study of aUtologous CD19 CAR T cElls for therapy refractory chronic GvHD (CURE-cGvHD) Recruiting

2025-524468-40-00 Phase I (Other) 1 country
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Phase III 2 countries DEXAMETHASONE; IBERDOMIDE; ISATUXIMAB
Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial Recruiting

2024-516544-26-00 Phase II 1 country TENECTEPLASE
CLonE-specific CAR T-Cell therapy in relapsed or refractory AL amyloidosis - a single-center Phase I trial (CLEAR AL) Recruiting

2025-520790-39-00 Phase I (Other) 1 country
A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA Recruiting

2025-521530-28-00 Phase I/II 1 country IDECABTAGENE VICLEUCEL
A phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL Recruiting

2024-519532-16-00 Phase I/II 1 country CNTY-101
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blin… Recruiting

2023-506887-15-00 Phase II 1 country INTESTIFIX; VANCOMYCIN HYDROCHLORIDE
Differences in absorption via oral route and via oral mucosa of hydrocortisone from 2-dimensionally printed dissolvable films in healthy vol… Recruiting

2024-517298-26-00 1 country
Maternal oxygen therapy during pregnancy for unborn babies with underdeveloped structures on the left side of the heart Recruiting

2024-512679-11-00 Phase III 1 country OXYGEN
A phase II, multicenter, 1:1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of bolus applicatio… Recruiting

2024-511037-35-00 Phase II 1 country CICLOSPORIN
Pasireotide as Maintenance Treatment with monthly deep intramuscular injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Sma… Recruiting

2024-511935-86-00 Phase II 1 country
Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in patient… Recruiting

2024-512459-19-00 Phase IV 1 country GUSELKUMAB
Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge) Recruiting

2023-503938-52-00 Phase II 1 country PERAMPANEL
Randomized clinical study to analyse the effects of dapagliflozin on renal morphology and renal perfusion in patients with impaired renal f… Recruiting

2024-517885-40-00 Phase IV 1 country DAPAGLIFLOZIN
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants wit… Recruiting

2024-517382-17-00 Phase II 1 country BORTEZOMIB; DARATUMUMAB; JNJ-79635322; LENALIDOMIDE; TALQUETAMAB; TECLISTAMAB
A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutaneous administration o… Recruiting

2023-510376-31-00 Phase II 1 country ANAKINRA
Early Stage Follicular LymphOma and RadioTherapy PLUS anti-CD20 Antibody Recruiting

2023-509278-41-00 Phase III 1 country OBINUTUZUMAB; RITUXIMAB
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-… Recruiting

2024-510616-73-00 Phase III 1 country
An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting

2023-508251-39-00 Phase III 2 countries ABATACEPT; APREMILAST; CERTOLIZUMAB PEGOL; GOLIMUMAB; GUSELKUMAB; IXEKIZUMAB; RI…

Showing 1–24 of 38 trials

← All sponsors A–Z